Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH1R132H-DC Vaccine in Gliomas
NCT02771301Unknown
- Sponsor
- Hebei Yanda Hospital
- Start
- Feb 2016
- Primary completion
- Jan 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of IDH1R132H dendritic cell vaccine in glioma, sponsored by Hebei Yanda Hospital. Primary endpoint: Safety and Efficacy of IDH1R132H dendritic cell vaccine at 2 years. Status: unknown.
02
Drugs
IDH1R132H dendritic cell vaccine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02771301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771301.